Drug Discovery World

FEBRUARY 22, 2024

Under the terms of the agreement, the companies plan to combine Kelonia’s iGPS with Xyphos’ ACCEL technology to develop in vivo CAR-T cell therapies targeting up to two programmes. The post Companies agree $800m deal for off-the-shelf in vivo CAR-T cell therapy appeared first on Drug Discovery World (DDW).

In-Vivo 52

In-Vivo Licensing Licensing Sales 52

Bio Pharma Dive

JANUARY 6, 2023

The Takeda-backed biotech revealed it’s raised $85 million in new funding alongside announcing the acquisition of gene editing startup Twelve Bio.

In-Vivo 304

In-Vivo Gene Editing Gene 304

Bio Pharma Dive

MARCH 2, 2023

The announcement, which follows recent regulatory setbacks for some of Intellia’s peers, is a “big win” for the gene editing field, according to one analyst.

Gene Editing 294

Gene Editing In-Vivo Gene Drugs 294

Drug Discovery World

NOVEMBER 14, 2023

Verve-101 is an investigational, in vivo base editing medicine designed to be a single-course treatment that inactivates the PCSK9 gene in the liver to durably lower blood LDL-C. “Of The post Single-course in vivo base editing therapy proven to lower cholesterol appeared first on Drug Discovery World (DDW).

In-Vivo 52

In-Vivo Gene Editing Gene Genome 52

BioPharma Reporter

JUNE 13, 2023

Sygnature Discovery has launched an in vivo inflammation model, that the company says is âexciting but only the beginningâ of understanding life-limiting neuroinflammatory conditions.

In-Vivo 52

In-Vivo Development 52

Bio Pharma Dive

MARCH 14, 2024

The Swedish biotech will use the investment to advance a kind of personalized cancer therapy that reprograms tumor cells inside the body.

In-Vivo 126

In-Vivo 126

Bio Pharma Dive

OCTOBER 23, 2023

since late last year as the FDA sought more details on Verve’s in vivo treatment for heart disease. The trial, which is ongoing in the U.K. and New Zealand, has been on hold in the U.S.

In-Vivo 338

In-Vivo Trials 338

XTalks

OCTOBER 20, 2023

Intellia said NTLA-2001 is the first investigational in vivo CRISPR-based gene editing therapy cleared to enter late-stage clinical development. As an in vivo therapy, it can edit genes inside the body rather than in cells extracted from patients. ATTR amyloidosis is a rare, progressive and fatal disease.

In-Vivo 52

In-Vivo Gene Editing Trials Gene 52

Scienmag

SEPTEMBER 28, 2020

CIC biomaGUNE researchers have demonstrated the restoring in vivo of the connection between neurons, yielding functional results Credit: Author: Pedro Ramos / CIC biomaGUNE Research conducted by two groups at the Center for Cooperative Research in Biomaterials CIC biomaGUNE and one at SISSA, Scuola Internazionale Superiore di Studi Avanzati (Italy), (..)

In-Vivo 96

In-Vivo Research Engineer Medicine 96

Pharmaceutical Technology

MARCH 21, 2024

Capstan Therapeutics has secured $175m Series B financing to advance its lead in vivo CAR-T candidate, CPTX2309, for autoimmune disorders.

In-Vivo 245

In-Vivo 245

pharmaphorum

MAY 26, 2023

Virtual workshop - Unveiling the Potency-Efficacy Connection: Integrating Functional Assay Readouts for In Vivo Insights Mike.Hammerton Fri, 05/26/2023 - 14:00 Bookmark this

In-Vivo 52

In-Vivo 52

Drug Discovery World

SEPTEMBER 14, 2022

The post The latest MHC class I & II deficient in vivo platform humanised with PBMCs appeared first on Drug Discovery World (DDW). How this platform can support a wide range of immunological studies, especially those containing T cells responses. The versatility of this platform to various research disciplines.

In-Vivo 52

In-Vivo Containment Drugs Research 52

Bio Pharma Dive

OCTOBER 3, 2023

The longtime partners believe that, by combining their technologies, they can create “in vivo” genetic medicines for nervous system and muscular disorders.

Gene Editing 256

Gene Editing In-Vivo Gene Genetics 256

Drug Discovery World

SEPTEMBER 14, 2022

Hu-PBMC mice are used as in vivo models to study and evaluate compounds for T cell immune modulation, infectious diseases and graft rejection research. The post The latest MHC class I & II deficient in vivo platform humanised with PBMCs appeared first on Drug Discovery World (DDW). Download here.

In-Vivo 52

In-Vivo Containment Research Drugs 52

BioTech 365

NOVEMBER 9, 2020

LIfT BioSciences N-LIfT Cell Therapy Successfully Infiltrates Pancreatic Tumours In-vivo LIfT BioSciences N-LIfT Cell Therapy Successfully Infiltrates Pancreatic Tumours In-vivo LIfT BioSciences N-LIfT Cell Therapy Successfully Infiltrates Pancreatic Tumours In-vivo London, 9 November 2020 ­–LIfT BioSciences, a biotech company developing (..)

In-Vivo 52

In-Vivo Development 52

Bio Pharma Dive

JULY 17, 2023

Scribe will receive $40 million upfront from Sanofi in a collaboration initially focused on developing an in vivo gene editing treatment for sickle cell disease.

Gene Editing 237

Gene Editing Gene In-Vivo Research 237

Pharmaceutical Technology

JULY 18, 2023

Scribe Therapeutics and Sanofi have expanded partnership to progress the development of in vivo genetic therapies to treat genomic diseases.

Genetics 246

Genetics In-Vivo Development Genome 246

Scienmag

AUGUST 12, 2020

Researchers in China have taken the first step towards a new way of treating gastric wounds by using a microrobot combined with the new concept of “in situ in vivo bioprinting” to carry out tissue repair inside the body.

In-Vivo 72

In-Vivo Research Engineer Medicine 72

Pharmaceutical Technology

APRIL 26, 2024

Regeneron Pharmaceuticals has collaborated with Mammoth Biosciences to develop in vivo clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapies.

Gene Editing 130

Gene Editing Gene In-Vivo Development 130

Bio Pharma Dive

JANUARY 31, 2023

The pipeline of CAR-T therapies and ex vivo gene therapies has swelled in recent years, but manufacturing hasn’t been able to keep up with demand.

Gene 287

Gene In-Vivo Gene Therapy Manufacturing 287

Bio Pharma Dive

FEBRUARY 22, 2023

The messenger RNA specialist said Wednesday it is teaming up with Life Edit Therapeutics to develop therapies that can modify genes “in vivo.”

Gene Editing 255

Gene Editing Gene In-Vivo RNA 255

Bio Pharma Dive

NOVEMBER 29, 2022

In this continuing series, BioPharma Dive examines new areas of biotech investment and startup activity, such as next-generation RNA medicines, TYK2 inhibitors and in vivo CAR-T.

In-Vivo 240

In-Vivo RNA Research Medicine 240

Bio Pharma Dive

NOVEMBER 11, 2020

The biotech won a grant from the foundation two days after dosing the first patient in a study of an in vivo CRISPR medicine, a milestone for the company and the technology.

In-Vivo 364

In-Vivo Medicine 364

BioTech 365

OCTOBER 25, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Intellia, LogicBio fuel hope for in vivo gene editing with new animal data in rare diseases: report.Intellia, LogicBio fuel hope for in vivo gene editing with new … Continue reading →

Gene Editing 40

Gene Editing In-Vivo Gene Research 40

BioTech 365

AUGUST 25, 2021

Precision BioSciences to Host In Vivo Gene Editing R&D Event on September 9, 2021 Precision BioSciences to Host In Vivo Gene Editing R&D Event on September 9, 2021 DURHAM, N.C.–(BUSINESS –(BUSINESS WIRE)–Precision BioSciences, Inc.

Gene Editing 40

Gene Editing In-Vivo Gene 40

Scienmag

SEPTEMBER 29, 2021

Furthermore, the current understanding of beta cell function is mostly derived from studies of ex vivo isolated islets in rodent […]. However, the highly regulated process of insulin secretion, especially its molecular features and the stimuli behind this process have not yet been fully understood.

In-Vivo 52

In-Vivo Insulin Development Regulation 52

Bio Pharma Dive

OCTOBER 25, 2023

The study results, while only from three participants, offer a glimpse at how one of the few in vivo CRISPR therapies in U.S. human testing is working.

Gene Editing 148

Gene Editing In-Vivo Gene 148

BioSpace

JUNE 16, 2024

The plethora of genes involved in obesity presents an intriguing opportunity for both gene silencing and ex vivo gene therapy approaches.

Gene Silencing 109

Gene Silencing In-Vivo Genetics Gene Therapy 109

BioTech 365

DECEMBER 3, 2021

CAMP4 Presents In Vivo Data Supporting Novel Therapeutic Strategy for Dravet Syndrome at American Epilepsy Society Annual Meeting CAMP4 Presents In Vivo Data Supporting Novel Therapeutic Strategy for Dravet Syndrome at American Epilepsy Society Annual Meeting – Upregulation of SCN1A … Continue reading →

In-Vivo 52

In-Vivo 52

BioTech 365

MAY 26, 2021

Biomedical Microelectromechanical Systems Markets: In Vivo Devices and Microcantilever Sensors – Global Forecast to 2025 – ResearchAndMarkets.com Biomedical Microelectromechanical Systems Markets: In Vivo Devices and Microcantilever Sensors – Global Forecast to 2025 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The (..)

In-Vivo 40

In-Vivo Marketing 40

BioTech 365

APRIL 8, 2021

Nimbus Therapeutics Presents In Vivo Data Showing Single-Agent and Combination Activity of HPK1 Inhibitor Nimbus Therapeutics Presents In Vivo Data Showing Single-Agent and Combination Activity of HPK1 Inhibitor CAMBRIDGE, Mass.–(BUSINESS

In-Vivo 52

In-Vivo Medicine 52

Medical Xpress

MAY 16, 2023

That was the case when Thilini Gamage was to carry out one of the studies in her doctoral work with Professor Eirik Frengen at the Institute of Clinical Medicine, University of Oslo. They study gene variation and mutations that cause rare genetic diseases. A mutation is a permanent change in the genetic material.

In-Vitro 98

In-Vitro In-Vivo Genetic Disease Genetics 98

Drug Discovery World

JULY 3, 2024

Circio has announced updated in vivo data that demonstrates a substantial durability advantage of Circio’s circVec technology over conventional mRNA expression. design is performing very well in vivo , and Circio has now validated expression for up to five months. design. “The circVec 2.1

In-Vivo 59

In-Vivo Gene Therapy RNA Gene 59

BioTech 365

DECEMBER 23, 2021

Synthekine Announces Publication of Preclinical Data Demonstrating In Vivo Control of CD19 CAR-T Cells with its Orthogonal IL-2 System Synthekine Announces Publication of Preclinical Data Demonstrating In Vivo Control of CD19 CAR-T Cells with its Orthogonal IL-2 System Orthogonal IL-2 … Continue reading →

In-Vivo 52

In-Vivo 52

BioTech 365

AUGUST 31, 2021

Ixaka to present in vivo gene delivery platform for CAR-T and related bioproduction challenges at 6th CAR TCR Summit Ixaka to present in vivo gene delivery platform for CAR-T and related bioproduction challenges at 6th CAR TCR Summit CSO, Cecile … Continue reading →

In-Vivo 52

In-Vivo Gene 52

BioTech 365

JANUARY 10, 2022

Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a … Continue reading →

In-Vivo 52

In-Vivo Research 52

BioSpace

SEPTEMBER 29, 2021

EDIT-101 targets a disease-causing mutation in the CEP290 gene that causes degeneration in ocular photoreceptor cells, which are critical for normal vision.

In-Vivo 106

In-Vivo Gene 106